Lupin gains after Pithampur facility gets EIR from USFDA

Lupin gained 1.62% to Rs 868.1 afterthe drug major said its Pithampur Unit-1 facility received EIR from the US drug regulator.

Lupin on Thursday announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-1, India facility. The inspection for the facility was conductedby the USFDA between 3rd and 11th February 2020 and concluded with two observations.

Commenting on the receipt of the EIR, Nilesh Gupta, Managing Director, Lupin said, We are very happy to have received the EIR for our Pithampur Unit-1 facility with Voluntary Action Indicated (VAI) status. Continuous improvement of our quality and compliance standards across all our manufacturing sites is a key focus area for the company and we are committed to work with the U.S. FDA to manufacture and supply products of the highest quality from all our manufacturing sites.

On Wednesday (29 April), Lupin announced that it received tentative approval for its Arformoterol Tartrate Inhalation Solution from the US drug regulator. The solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).

Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Powered by Capital Market - Live News